James M. Larkin
Expertise in
5
conditions

James M. Larkin

College Green, 
Dublin, L, IE 
Expertise in
5
conditions
College Green, 
Dublin, L, IE 

Overview

James Larkin practices practicing medicine in Dublin, Ireland.

Mr. Larkin is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Melanoma, Renal Cell Carcinoma (RCC), Metastatic Brain Tumor, Kidney Transplant, and Nephrectomy.

He is actively involved in clinical research, co-authoring 419 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

College Green, Dublin, L, Ireland
Other Locations
123 St Stephen's Green 2, Dublin, L, Ireland
4-5 Lincoln Place, Dublin, L, Ireland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma
Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma
Enrollment Status: Terminated
Publish Date: April 23, 2026
Intervention Type: Radiation, Drug
Study Phase: Phase 2
A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)
A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)
Enrollment Status: Terminated
Publish Date: June 06, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
A-PREDICT: A Phase II Study Of Axitinib In Metastatic Renal Cell Cancer in Patients Unsuitable for Nephrectomy
A-PREDICT: A Phase II Study Of Axitinib In Metastatic Renal Cell Cancer in Patients Unsuitable for Nephrectomy
Enrollment Status: Completed
Publish Date: November 21, 2024
Intervention Type: Drug
Study Drug: Axitinib
Study Phase: Phase 2
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Enrollment Status: Withdrawn
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drugs: IMCgp100, Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
Enrollment Status: Completed
Publish Date: June 07, 2024
Intervention Type: Drug
Study Drugs: LGX818, MEK162, Nivolumab, Ipilimumab
Study Phase: Phase 2
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, IMO-2125
Study Phase: Phase 3
A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma
A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Drug: PLX3397
Study Phase: Phase 2
View 6 Less Clinical Trials

417 Total Publications

Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy.
Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy.
Journal: Journal for immunotherapy of cancer
Published: August 10, 2026

Frequently Asked Questions about James M. Larkin

Is James M. Larkin a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. James M. Larkin is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does James M. Larkin participate in research or clinical trials?

Yes. James M. Larkin has published 417 articles and abstracts on conditions like Melanoma. You can view a list of James M. Larkin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Larkin's expertise for a condition
ConditionClose
View All 36 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile